PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34648657-1	2022	In randomized clinical trials, the androgen receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC).	enzalutamide	63-75	androgen receptor	Homo sapiens	35-52